Henlius announced that Mr. Wenjie Zhang will officially join and serve as Senior Vice President (SVP) and Chief Commercial Operation Officer (CCO) of the company on March 4th, responsible for the company's overall commercial planning and the formulation of product marketing strategy, to build a professional and efficient international commercial operation team.
Mr. Wenjie Zhang has more than 25 years of commercial operation experience in the pharmaceutical industry. He has successively served as the head of the oncology and specialty therapeutics business unit of Bayer Schering Pharma, Vice President of Business Unit 2 of Roche, Executive Director of Amgen Japan and Asia Pacific market, and General Manager of Amgen China, etc. Mr.Wenjie Zhang has successfully grew the Roche oncology portfolio including Avastin®(bevacizumab), Tarceva®(erlotinib) and Mabthera®(rituximab) in the China market and launched multiple products in China including Nexavar, Kogenate and Betaferon. He made outstanding achievements in pipeline planning, franchise strategy, and franchise marketing of multiple oncology products.
Dr. Scott Liu, Co-founder, President and Chief Executive officer of Henlius, welcomed and thanked Mr. Zhang for joining us. In recent years, Henlius has been actively involved in the field of monoclonal antibodies, and its products have successively reached the late stage of clinical development and commercial manufacturing. With the company's products being launched in the future, Henlius has great potential in the commercial operation of products!
“The emerging bio-pharmaceutical companies in China are developing rapidly, and there is no doubt that Henlius has become one of the leaders in domestic biopharmaceutical field with a more promising future, regardless of product quality, technical ability, management team, aswell as Fosun's powerful support.” said Mr. Wenjie Zhang, “I am very honored to have this opportunity to join Henlius, and I look forward to working with colleagues of Henlius in the future to build Henlius as a world's leading biopharmaceutical company, benefiting more patients in China and around the world.”
With its independent core competitiveness of high efficiency and innovation, Henlius has been leading the monoclonal antibody bio-pharmaceutical industry in China for a long time. On the basis of continuous innovation and upgrading, Henlius will also continue to make efforts in the international operation and build a biomedical industry chain platform from research, development, manufacturing and commercialization. We are doing continuous innovation, excellent operation and committed to become the world's most admired biomedical company.